Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
ID: 336392Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/336392

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-062.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer" (R21 Clinical Trial Not Allowed), aimed at supporting exploratory research on the human microbiome's role in anti-tumor immune responses. This initiative seeks to elucidate mechanisms by which specific microbes or their metabolites can influence tumor immunity, with a focus on identifying novel molecular targets for cancer prevention strategies. The research is particularly relevant for understanding the gut microbiome's impact on cancer development and immune responses, especially in individuals with altered gut microbiota. Eligible applicants include various educational institutions, nonprofits, and government entities, with a funding ceiling of $275,000 available over a two-year period. Applications must be submitted by January 7, 2025, and inquiries can be directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-062-Full-Announcement.html
    PAR-22-062.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Cancer Institute (NCI), has issued a Funding Opportunity Announcement (FOA) for research on the role of the human microbiome in enhancing anti-tumor immune responses, titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer" (R21 Clinical Trial Not Allowed). This exploratory/developmental research aims to investigate mechanisms by which specific microbes or their metabolites can influence tumor immunity, ultimately identifying molecular targets for cancer prevention. Notable areas of interest include studying the gut microbiome's impact on cancer development and immune responses, particularly in patients with altered gut microbiota. The FOA invites applications focused on innovative research directions and requires rigorous assessment of how host-microbe interactions can be optimized for anti-tumor efficacy. Eligible organizations include educational institutions, nonprofits, and government entities, with a budget limit of $275,000 over two years. Applications must follow specific submission procedures via Grants.gov or NIH's ASSIST system, and peer-reviewed applications will be assessed based on their scientific merit, innovation, and relevance to public health goals. This opportunity emphasizes the critical intersection of microbiology and immunology in cancer research and prevention strategies.
    Similar Opportunities
    Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer," aimed at supporting basic research into the human microbiome's role in anti-tumor immune responses. Applicants are required to develop innovative projects that explore the interactions between specific microbes or their metabolites and host immune responses, with a focus on identifying mechanisms that may enhance or inhibit tumor formation. This initiative is significant for advancing cancer research and understanding the implications of microbiome interactions in immunology. The funding, administered under the R01 Research Project Grant mechanism, has no budget limit and is open to a diverse range of eligible organizations, with a project duration of up to five years. Interested parties can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by January 7, 2025.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs," aimed at exploring innovative strategies for cancer therapy and diagnostics utilizing microorganisms. This R21 grant supports exploratory projects that investigate the interactions between tumors and microorganisms, such as bacteria and viruses, with a focus on enhancing immune responses and developing new imaging technologies, particularly for solid tumors and oral cancers. The initiative seeks to address critical gaps in current cancer treatment modalities and encourages proposals that demonstrate innovative, multi-disciplinary approaches. Eligible applicants can request funding up to $275,000 over a two-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (R01 Clinical Trial Not Allowed), aimed at advancing research on the use of microorganisms for cancer treatment and diagnostics. This initiative invites grant applications that explore the interactions between bacteria, archaebacteria, bacteriophages, and tumors, focusing on their potential to enhance cancer imaging, therapeutics, and diagnostics, particularly for solid tumors. The program encourages multidisciplinary collaborations and aims to address current limitations in cancer therapies, with a significant emphasis on improving treatment outcomes in low-resource settings. Interested applicants can find more information and submit their proposals by May 7, 2025, and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Understanding Mechanisms and Outcomes of Trained Immunity" through the R21 grant mechanism, aimed at advancing research into innate immune memory, known as trained immunity. This initiative seeks to enhance understanding of the mechanisms, biomarkers, and functional implications of trained immunity, particularly in relation to immune system development, vaccine efficacy, and various diseases, while explicitly prohibiting clinical trials. The grant provides a maximum funding amount of $275,000, with applications accepted starting May 16, 2024, and a closing date of January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 exploratory research grant titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics." This grant aims to support preclinical and patient-based studies that investigate how incretin mimetics, specifically GLP-1 and GIP-1 receptor agonists, influence cancer risk, particularly in relation to obesity-related cancers such as thyroid and prostate cancers. The funding, which amounts to a maximum of $275,000 over two years, is intended for projects that do not involve clinical trials, with applications opening in January 2024 and a submission deadline of January 7, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering exploratory grants (R21 Clinical Trial Optional) aimed at advancing cancer control research. This funding opportunity encourages innovative approaches to understanding cancer etiology, behavior modification, and screening techniques, focusing on the early stages of impactful research that can significantly enhance population-based cancer research. Grants will provide up to $275,000 over two years, with a maximum of $200,000 available in a single year, and applications are due by October 8, 2024. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)" aimed at advancing innovative research into precision probiotic interventions. This initiative seeks applications that will investigate person-specific factors influencing probiotic responses, such as microbiome composition, age, sex, genetic background, and lifestyle, to identify subgroups that may benefit from tailored probiotic treatments. The funding is crucial for addressing variability in human responses to probiotics and aims to enhance health outcomes through targeted interventions. Applicants can request up to $350,000 per year for a maximum of four years, with the application deadline set for June 2, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-239.html.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infection in cancer development. This initiative encourages mechanistic and epidemiologic studies that explore how infections by multiple agents—both pathogenic and non-pathogenic—can influence cancer risk and progression, with a focus on known oncogenic agents, excluding HIV. Given the significant proportion of cancer cases linked to infectious agents, this research is crucial for developing novel prevention and treatment strategies. Interested applicants, including a variety of educational institutions and organizations, particularly those from underrepresented groups, must submit their applications by November 5, 2025, and can find further details and guidelines at the NIH website or contact NIH Grants Information at grantsinfo@nih.gov.